LianBio (LIAN): Price and Financial Metrics


LianBio (LIAN): $2.91

-0.09 (-3.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LIAN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LIAN Stock Price Chart Interactive Chart >

Price chart for LIAN

LIAN Price/Volume Stats

Current price $2.91 52-week high $16.37
Prev. close $3.00 52-week low $2.15
Day low $2.69 Volume 749,100
Day high $3.06 Avg. volume 456,033
50-day MA $3.68 Dividend yield N/A
200-day MA $0.00 Market Cap 315.08M

LianBio (LIAN) Company Bio


Lianbio operates in the healthcare industry focusing on pharmaceutical business. The company is based in Camana Bay, Cayman Islands.


LIAN Latest News Stream


Event/Time News Detail
Loading, please wait...

LIAN Latest Social Stream


Loading social stream, please wait...

View Full LIAN Social Stream

Latest LIAN News From Around the Web

Below are the latest news stories about LianBio that investors may wish to consider to help them evaluate LIAN as an investment opportunity.

LianBio Announces Mavacamten Granted Breakthrough Therapy Designation in China

SHANGHAI and PRINCETON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation in China for mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM). Breakthrough Therapy Designation

Yahoo | February 15, 2022

What Kind Of Investors Own Most Of LianBio (NASDAQ:LIAN)?

A look at the shareholders of LianBio ( NASDAQ:LIAN ) can tell us which group is most powerful. Institutions often own...

Yahoo | February 1, 2022

LianBio Announces First Patient Dosed in Registrational Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy

EXPLORER-CN trial designed to support regulatory filing in Mainland ChinaSHANGHAI, China and PRINCETON, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the first patient has been dosed in the Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). “With more than one mil

Yahoo | January 10, 2022

LianBio Announces Infigratinib Approved Under Special Named Patient Program for the Treatment of Cholangiocarcinoma in the Pilot Zone of Hainan Province in China

SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that infigratinib has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the special Named Patient Program (NPP), for the treatment of patients with previously treated, unresectable locally advanced or metastatic cholang

Yahoo | December 21, 2021

LianBio Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Initiated and completed dosing in pharmacokinetic (PK) study of mavacamten in healthy Chinese volunteers Initiated Phase 2a clinical trial of infigratinib in Chinese patients with gastric cancer and other advanced solid tumors Strengthened leadership team with appointment of scientific and commercial executives Completed initial public offering for gross proceeds of approximately $334.5 million, providing cash runway through 2023 SHANGHAI, China and PRINCETON, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE

Yahoo | December 9, 2021

Read More 'LIAN' Stories Here

LIAN Price Returns

1-mo -42.32%
3-mo -32.64%
6-mo -81.81%
1-year N/A
3-year N/A
5-year N/A
YTD -52.76%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0342 seconds.